LFM-A13: An antileukemic/antithrombotic agent

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: 2R44HL071288-02
Agency Tracking Number: HL071288
Amount: $750,000.00
Phase: Phase II
Program: SBIR
Awards Year: 2004
Solicitation Year: 2004
Solicitation Topic Code: N/A
Solicitation Number: PHS2004-2

Small Business Information
PARADIGM PHARMACEUTICALS, LLC
PARADIGM PHARMACEUTICALS, LLC, 2685 PATTON RD, ST. PAUL, MN, 55113
DUNS: N/A
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
Name: SANDEEP Mahajan
Phone: (651) 628-9988
Email: SMAHAJAN@IH.ORG

Business Contact
Name: HEATHER TIBBLES
Phone: (651) 697-0070
Email: HTIBBLES@IH.ORG

Research Institution
N/A

Abstract
DESCRIPTION (provided by applicant): We have rationally designed the leflunomide metabolite analog alpha-cyano-beta-hydroxy-beta-methyl-N-(2,5-dibromophenyl)-propenamide (LFM-A13) as a specific inhibitor of the protein tyrosine kinase, Bruton's tyrosine k

* Information listed above is at the time of submission. *